Our science

At Ipsen, the patient is at the heart of what we do. We continuously invest to innovate and deliver therapeutic solutions for the patient’s benefit.

Oncology

Neuroendocrine tumors, kidney, liver, pancreatic, bladder, and breast cancer

Ipsen’s commitment to oncology is demonstrated by its growing portfolio of therapies aimed at improving the lives of patients with neuroendocrine tumors, kidney cancer, pancreatic, bladder, and breast cancers.

 

Read more

Neuroscience

Spasticity in adults and children, cervical dystonia, hemifacial spasm, cerebral palsy

Ipsen is one of the global leaders in the discovery, development, manufacture and commercialization of neurotoxins.  Neuroscience is core to Ipsen’s specialty care business and is integral to the company’s overall strategy and long‐term growth.

 

Read more

Rare diseases

Pituitary pathologies and growth disorders

Ipsen continues to develop innovative medicines in rare diseases to address conditions with high unmet needs, with specific investment in pituitary pathologies and growth disorders.

 

Read more

Consumer HealthCare

Gastrointestinal disorders, neurodegenerative pathologies and rheumatology

Ipsen’s long-standing expertise spans the value chain, from active principle to finished product to the patient, with special expertise in gastrointestinal (GI) disorders, neurodegenerative pathologies and rheumatology, as well as a constantly expanding portfolio. We are also establishing a growing sustainable and autonomous Consumer Healthcare business.

 

Read more

 

R&D

Research & Development

Ipsen’s commitment to research & development is our bold promise to patients to launch at least one new drug or meaningful new indication every year.  We will secure our future by building a pipeline of innovative medicines.

 

Read more
In-White-75px-R

Latest jobs and updates

Visit our Linkedin page to find out about the latest jobs available

Our Linkedin
© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2019